8 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Development of Biomaterial-based Delivery Systems for Parkinson’s disease - an Integrated Pan-European Approach (BrainMatTrain)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,
BrainMatTrain focuses on a comprehensive understanding of Parkinson’s disease (PD), from basics to translation, fully supported by 8 full partners partner organisation (4 research institutions, 2 hospitals, 2 SMEs) and one partner organisation (SME specialist in device design). This ETN will educate and train 15 Earlty Stage Researchers (ESRs) in functioanlised biomaterials, materials science, fun ...
Voir le projet
8
Participants partenaires
TERMINÉ
Novel Stromal Cell Therapy for Diabetic Kidney Disease (NEPHSTROM)
Date du début: 1 mai 2015, Date de fin: 30 avr. 2019,
Type 2 diabetes will affect >500 million adults by 2040 and its secondary complications will generate enormous socioeconomic costs - in particular, diabetic kidney disease (DKD), which is already the most common cause of chronic kidney disease. DKD is associated with greatly increased mortality and frequently progresses to end stage renal failure. Pharmacotherapy, dialysis and transplantation repr ...
Voir le projet
12
Participants partenaires
TERMINÉ
Adverse Immune Signatures and their Prevention in Corneal Transplantation (VISICORT)
Date du début: 1 avr. 2014, Date de fin: 31 mars 2019,
"Immune system response is the most complex barrier to long-term success of tissue transplants/implants from allogeneic and bio-artificial sources. While newly developed tissue transplant procedures are not yet performed frequently enough for robust analysis of adverse immune responses in humans, corneal transplantation (CT) is a well-established allogeneic tissue transplant with >100,000 full- an ...
Voir le projet
12
Participants partenaires
TERMINÉ
Development of closed, scalable and AUTOmated robotic systems for therapeutic STEM cell manufacturing: aseptic systems from “Donor-to-Patient” (AUTOSTEM)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2018,
AUTOSTEM will develop closed, scaleable and automated systems for therapeutic cell manufacture. The project vision is a donor-to-patient system where all aspects of processing, from tissue harvest to patient delivery are fully closed and aseptic. The process will involve new methods of biological cell selection from marrow, fat or other tissues, bioreactors to achieve scale and media formulations ...
Voir le projet
10
Participants partenaires
TERMINÉ
MEsenchymal stem cells to Reduce Liver INflammation (MERLIN)
Date du début: 1 févr. 2014, Date de fin: 31 janv. 2018,
"Prevalence of liver disease is c6% (29 million people) in the EU with mortality rates from chronic liver diseases estimated at 14.3 per 100.000 in the EU-25 in 2004. Most liver diseases have a significant inflammatory component that underpins liver damage and fibrogenesis, yet current therapies have limited effectiveness. Safe novel anti-inflammatory therapies would satisfy a large unmet need for ...
Voir le projet
9
Participants partenaires
TERMINÉ
Decision-making within cells and differentiation entity therapies (DECIDE)
Date du début: 1 mars 2013, Date de fin: 28 févr. 2017,
"Our ITN has both scientific and therapeutic targets. Research in Work Package 1 (WP1) aims to advance understanding of normal blood cell development and why primitive cells fail to differentiate in acute myeloid leukaemia (AML). Research in WP2 will use the information gained from WP1 to develop ways of alleviating the differentiation block in AML and so deliver new agents for use in differentiat ...
Voir le projet
8
Participants partenaires
TERMINÉ
Repair of Diabetic Damage by Stromal Cell Administration (REDDSTAR)
Date du début: 1 nov. 2012, Date de fin: 31 oct. 2016,
50 million diabetic EU citizens are using approved anti-diabetic agents to control their glycaemia. However, suboptimal glycemic control leads to 6 progressive diabetic complications, namely: nephropathy, retinopathy, cardiomyopathy, neuropathy and foot ulceration. In 2010, 11% of EU adult deaths (634,000) were caused by diabetic complications. These distinct disorders have few effective medicines ...
Voir le projet
10
Participants partenaires
TERMINÉ
Utilisation of the mesenchymal stem cell receptome for rational development of uniform, serum-free culture conditions and tools for cell characterization (PurStem)
Date du début: 1 nov. 2008, Date de fin: 30 avr. 2012,
Stem cells offer a promising avenue to therapy for a wide range of complaints. However, for this potential to be realized, a consistent and plentiful supply of well-characterised stem cells is essential. There has been relatively little progress in the development of new culture technologies for the large-scale manufacture of mesenchymal stem cells (MSCs). There is a strong possibility that this ...
Voir le projet